This hormone helps control blood sugar levels by stimulating insulin production after we eat and by slowing down how quickly our stomach empties food
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has transformed the treatment of type 2 diabetes and obesity
Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended Important Safety Information for Wegovy WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
Is semaglutide or tirzepatide better for weight loss
Semaglutide, the generic name for the drug, was tested in clinical trials from 2016 to 2017, prior to approval by the FDA to treat type 2 diabetes in adults
Steps to Take If You Experience Discomfort Step 1: Stop eating immediately
